A Double-Blind Comparison of Fluvoxamine and Paroxetine in the Treatment of Depressed Outpatients

Kiev, Ari; Feiger, Alan D.

doi:10.4088/jcp.v58n0402

Cited by 70 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two previous prospective studies with no genetic variants considered have demonstrated no significant differences in clinical response to treatment of depression between the two SSRIs [49,50] . In our previous report, we hypothesized that the reasons for the different responses of the two in SERTPR s/s genotype carriers were related to their differences in potential serotonin uptake inhibition [9] .…”

Section: Discussionmentioning

confidence: 83%

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

et al. 2006

View full text Add to dashboard Cite

In this study, we tested the influence of the serotonin type 2A, 3A and 3B receptor genes (HTR2A, HTR3A, HTR3B) in addition to a polymorphism in the promoter region of the serotonin transporter (SERTPR), and investigated the different characteristics of clinical responses to paroxetine and fluvoxamine. A total of 100 Japanese patients affected by major recurrent depression were enrolled in a randomized 6-week study. The clinical response was evaluated using the Hamilton Rating Scale for Depression (HAM-D), and adverse drug reactions were assessed at each visit. Patients with the l allele of SERTPR showed a better response to SSRIs than s/s genotype carriers (p = 0.015–0.042), more significantly to fluvoxamine. The –1438G/G genotype of HTR2A was associated with a good response to SSRIs (p = 0.010–0.039), especially to fluvoxamine, and significantly with severe nausea in paroxetine-treated patients (p = 0.013). The 178C/C genotype of the HTR3A was associated with an antidepressant response (p = 0.022–0.042), and more significantly in paroxetine-treated patients (p = 0.002–0.042). These effects were independent of one another. We replicated the finding that the SERPTR polymorphism was associated with a response to SSRIs. We additionally found that HTR2A and HTR3A polymorphisms are associated with the efficacy, and the HTR2A polymorphism is also associated with adverse drug reactions. Furthermore, the effects of these polymorphisms varied from one SSRI to another and thus may depend on the characteristics of each SSRI.

show abstract

Section: Discussionmentioning

confidence: 83%

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

et al. 2006

View full text Add to dashboard Cite

show abstract

“…It is known that drugs administered for anxiety symptoms or depression can cause dyspepsia or abnormal bowel movements as side effects, 34,35 but only three patients in all of the analyzed studies failed to complete the study. One patient, who was taking medazepam, withdrew because of extreme drowsiness, and two patients, taking mianserin, withdrew because of sedation and vertigo.…”

Section: Discussionmentioning

confidence: 99%

Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review

et al. 2005

View full text Add to dashboard Cite

show abstract

“…A 7-week double-blind study in 60 depressed outpatients was performed to compare the clinical response to fluvoxamine and paroxetine [54]. Both treatment groups showed similar improvement regarding the HAM-D.…”

Section: Fluvoxaminementioning

confidence: 99%

Effects of Selective Serotonin Reuptake Inhibitors on Objective and Subjective Sleep Quality

2000

View full text Add to dashboard Cite

The purpose of this paper is to review the effects of selective serotonin (5-HT) reuptake inhibitors on objective and subjective sleep and awakening quality measures. Polysomnography (PSG) demonstrated in both healthy volunteers and depressed patients a decrease in sleep efficiency and total sleep time, a lengthening of sleep latency and a deterioration in sleep continuity, including an increase in the number of awakenings and wake time during the total sleep period. Sleep architecture mostly showed an increase in S1 and S2 and a decrease in S3, S4 and REM sleep as well as a lengthening of REM latency. Objective awakening quality, if measured at all by psychometry, generally showed no decrements. Concerning subjective sleep and awakening quality, normals demonstrated either no changes or a tendency towards a deterioration, while in patients some improvement was observed. Reasons for this discrepancy will be discussed. Novel 5-HT reuptake inhibitors with additional modes of action such as 5-HT2 antagonism (e.g. trazodone, nefazodone) are more likely to improve objective and subjective sleep quality, although some shortcomings may be inherent in regard to comorbidity (e.g. sleep-related breathing disorders). Thus, PSG seems to be a necessity for diagnosis and treatment of complex sleep disorders.

show abstract

A Double-Blind Comparison of Fluvoxamine and Paroxetine in the Treatment of Depressed Outpatients

Cited by 70 publications

References 0 publications

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review

Effects of Selective Serotonin Reuptake Inhibitors on Objective and Subjective Sleep Quality

Contact Info

Product

Resources

About